Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Acting Rx-to-OTC Switch Review Leader Prioritizes Personnel

This article was originally published in The Tan Sheet

Executive Summary

Shaw Chen, acting director of FDA’s Division of Nonprescription Clinical Evaluation, wants to stabilize the division’s staffing during a period of management transition. On the same CHPA conference panel, OTC monograph division chief Scott Furness shares some good news on time and extent applications.

You may also be interested in...



Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews

The Public Access to SunScreens Coalition will recommend a user fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.

OTC Firms Should Improve Monograph Compliance, Registration – CDER

CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel